Overview
Dr Judd Moul joined the Duke faculty in mid 2004 after a career in the US Army Medical Corps mainly at Walter Reed Army Medical Center. He is a retired colonel and a noted researcher and clinician in the area of prostate cancer and is a urologic oncologist. He served as the division chief of Duke Division of Urology from 2004 to 2011 and was named the James H Semans MD Professor of surgery in 2009 becoming Duke's first named endowed chair for urology. He was awarded the Gold Cystoscope Award from the American Urologic Association as well as Castle Connelly Physician of the year for Clinical Medicine in 2009. He has performed more than 1300 radical prostatectomies since joining the Duke faculty and is committed to outcomes research on this series and in other areas of prostate cancer. He served as the Editor for Prostate Cancer and Prostatic Dissease, a Nature Medicine journal, for more than a decade and is a popular speaker and lecturer having been visiting professor and keynote speaker throughout the US and the World. He is very committed to training residents and mentoring students and trainees.
Office Hours
Clinic days: Tuesday and Thursday from 8am to 530pm
OR Days: 1st,3rd and 5th Mondays and selected Wednesdays and Fridays
Telehealth Clinics 2nd and 4h Mondays as selected other days
OR Days: 1st,3rd and 5th Mondays and selected Wednesdays and Fridays
Telehealth Clinics 2nd and 4h Mondays as selected other days
Current Appointments & Affiliations
James H. Semans, M.D. Distinguished Professor of Urologic Surgery, in the School of Medicine
·
2009 - Present
Urology,
Clinical Science Departments
Professor of Urology
·
2005 - Present
Urology,
Clinical Science Departments
Professor in Anesthesiology
·
2012 - Present
Anesthesiology,
Clinical Science Departments
Member of the Duke Cancer Institute
·
2004 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Real-world analyses of major adverse cardiovascular events and mortality risk after androgen deprivation therapy initiation in black vs. white prostate cancer patients.
Journal Article Prostate Cancer Prostatic Dis · December 2025 BACKGROUND: Prostate cancer(PCa) patients treated with androgen deprivation therapy(ADT) may experience major adverse cardiovascular events(MACE) [1]. Racial disparities in PCa incidence and outcomes have been noted. In contrast to older studies, three rec ... Full text Link to item CiteThe changing face of castrate resistant prostate cancer.
Journal Article Prostate Cancer Prostatic Dis · September 2025 Full text Link to item CiteComparative Economic Evaluation of Radical Prostatectomy, Radiation, and Ablative Techniques in the Management of Localized Prostate Cancer.
Journal Article Cancers (Basel) · August 28, 2025 Background: To compare the costs of open retropubic radical prostatectomy (RRP), robotic-assisted radical prostatectomy (RALP), intensity-modulated radiation therapy (IMRT), low-dose brachytherapy (LDBT), stereotactic body radiotherapy (SBRT), cryotherapy ... Full text Link to item CiteRecent Grants
A Prospective Trial - Evaluation of ExoDx Prostate in Men with Prostate Cancer in an Active Surveillance Regimen
Clinical TrialPrincipal Investigator · Awarded by Exosome Diagnostics, Inc. · 2022 - 2026Phase III Randomized Efficacy and Safety Study
Clinical TrialPrincipal Investigator · Awarded by Medivation, Inc. · 2016 - 2026NWU22-12-01 A PHASE 2 PLACEBO-CONTROLLED TRIAL OF UROLITHIN A SUPPLEMENTATION IN MEN WITH PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY
ResearchCo Investigator · Awarded by Northwestern University · 2024 - 2025View All Grants
Education, Training & Certifications
Thomas Jefferson University ·
1982
M.D.
Pennsylvania State University ·
1979
B.S.